Meningitis is a type of disease that affects brain and spinal cord. Efforts are being directed towards combating the rising burden of the disease. Market Research Future (MRFR) has asserted in its recent study that The Meningitis Diagnosis and Treatment Market size is expected to rise to a valuation of USD 185 million by 2030, rising at 4.1% CAGR over the forecast period from 2022 to 2030. Investments in research projects are poised to increase in finding more effective treatment methods. Rising investments in drug research are further poised to boost the growth pattern of the meningitis diagnosis and treatment market over the next couple of years.

Increasing awareness about the fatal adverse effects of the disease is poised to catapult the meningitis diagnosis and treatment market on upward trajectory. Also, the rising burden of the disease is expected to have a favorable impact on the growth pace of the market in the forthcoming years. It has been studied in this report that the rising demand for point of care diagnostics is projected to catalyze expansion of the meningitis diagnosis and treatment market over the next couple of years. On the contrary, lack of awareness with regard to the disease in developing regions is expected to undermine market growth in the ensuing years.

Competitive Dashboard:

Top players in the global meningitis diagnosis and treatment market have been assessed in the share analysis covered in this MRFR report. These players are B. Braun Melsungen AG, Siemens Healthcare Private Limited, Sanofi, Pfizer Inc., GlaxoSmithKline plc, Baxter, Merck KGaA, Abbott, Bio-Rad Laboratories Inc., Quest Diagnostics Inc., Thermo Fisher Scientific Inc., Luminex Corporation, Cepheid, and F. Hoffman-La Roche Ltd., Pfizer Inc.

Market segmentation:

By type, the global meningitis diagnosis and treatment market have been segmented into viral meningitis, bacterial meningitis, fungal meningitis, and others. Among these, the viral meningitis segment held the largest share of the market closely trailed by the bacterial meningitis segment in 2017. These segments held 40% of the total share of the market together. Both of these segments are assessed to exhibit remarkable growth in the years to come. 

By service, the meningitis diagnosis and treatment market has been segmented into treatment and diagnosis. The treatment segment has been further sub-segmented into antibiotics, antifungal drugs, steroids, and others. The diagnosis segment has been sub-segmented into imaging, blood tests, lumbar puncture, and others. The treatment segment is anticipated to dictate the expansion of the market and expand at a relatively higher CAGR over the assessment period.

By End-user, the global meningitis diagnosis and treatment market has been segmented into hospitals & clinics, diagnostic centers, and others. Among these, the hospitals & clinics segment accounted for the maximum share of the market in 2017 and earned revenues worth USD 274.12 Mn. The segment is touted to demonstrate the highest CAGR of 3.54% across the projection period.

Regional Analysis:

The geographical evaluation of the global meningitis diagnosis and treatment market encompasses four major regions – Americas, the Middle East & Africa (MEA), Europe, and Asia Pacific. Americas is poised to hold the dominant share of the market followed by Europe. Americas is prognosticated to benefit from the rapid developments in the healthcare sector over the next few years. Increasing investments in research & development are projected to accelerate revenue creation in the Europe meningitis diagnosis and treatment market over the next few years. Asia Pacific is likely to exhibit the fastest growth rate in the forthcoming years. The regional market could grow at a rate of 4.07% across the assessment period. 

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.